Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), a biopharmaceutical company focused on psychedelics for mental health, announced Tuesday that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of the major depressive disorder (MDD). CYB003 is designed to potentially address the challenges and limitations of oral psilocybin.
Based on preclinical data, CYB003 “achieved less variability in plasma levels, faster onset of action, and shorter duration of effect. These preclinical data demonstrated that CYB003 has the potential to reduce the time and resource burden on patients, providers, and payers, and possibly improve scalability and accessibility of treatment,” Cybin reported in a press release.
A ‘tremendous milestone for Cybin’
“To commence dosing in our first-in-human Phase 1/2a trial is a tremendous milestone for Cybin, …